Tower Research Capital (TRC)’s Cognition Therapeutics CGTX Stock Holding History
Bought
Maintained
Sold
Other funds holding CGTX
C
CM
Tower Research Capital (TRC)'s CGTX Position: Q3 2026 in Review
Tower Research Capital (TRC) opened a new position in Cognition Therapeutics (CGTX) in Q3 2026: 100 shares worth $96. The stake represents ﹤0.01% of the portfolio and ranks #5750 among its holdings. This is a return to the name: Tower Research Capital (TRC) previously reported a position in CGTX as recently as Q1 2026.
Tower Research Capital (TRC) first reported a position in CGTX in Q2 2022 and has held it in 15 quarters since. The position peaked at $17.6K in Q2 2024. 78 funds tracked by Wall St. Rank hold CGTX as of Q3 2026.
- Tower Research Capital (TRC) held 100 shares of Cognition Therapeutics worth $96 as of Q3 2026.
- Cognition Therapeutics was a new Tower Research Capital (TRC) position in Q3 2026.
- Cognition Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q3 2026, its #5750 holding.
- Tower Research Capital (TRC) first reported a position in Cognition Therapeutics in Q2 2022 and has held it in 15 quarters since.
- Tower Research Capital (TRC)'s Cognition Therapeutics position peaked at $17.6K in Q2 2024.
- 78 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q3 2026.
Based on Tower Research Capital (TRC)'s 13F filing for Q3 2026, filed 16 Nov 2026.